共 309 条
[1]
Arteaga CL(2011)Treatment of HER2-positive breast cancer: current status and future perspectives Nat Rev Clin Oncol 9 16-32
[2]
Sliwkowski MX(1989)Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707-712
[3]
Osborne CK(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783-792
[4]
Perez EA(2001)Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 10869-10874
[5]
Puglisi F(2012)The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups Nature 486 346-352
[6]
Gianni L(2010)Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer J Clin Oncol Off J Am Soc Clin Oncol 28 1301-1307
[7]
Slamon DJ(2006)Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733-2743
[8]
Godolphin W(2014)Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol Off J Am Soc Clin Oncol 32 3626-3633
[9]
Jones LA(2020)Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer N Engl J Med 382 597-609
[10]
Holt JA(2014)Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline J Clin Oncol Off J Am Soc Clin Oncol 32 2078-2099